Altogether, 7/11 double mutation carriers (excluded from the analysis of clinicopathological data) carried at least one mutation in high-risk melanoma (POT1/CHEK2) or syndromic (ATM/WRN, BRCA1, BRCA2 (2x), CHEK2/RAD51D, NBN) genes (Table 3). This evidence concerns the gene POT1 and melanoma.